PROACTIVE study

Study / Research

A cardiovascular safety study for pioglitazone involving 5,238 participants, which showed that the drug positively impacted major adverse cardiovascular events (MACE), with weight gain being a predictor of reduced mortality.

Mentioned in 1 video

Videos Mentioning PROACTIVE study

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD

A cardiovascular safety study for pioglitazone involving 5,238 participants, which showed that the drug positively impacted major adverse cardiovascular events (MACE), with weight gain being a predictor of reduced mortality.